Operaciones Cerevel Therapeutics Holdings, Inc. - CERE CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.11 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024068% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.001846% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Estadísticas clave
| Cierre previo* | 26.94 |
| Abrir* | 25.72 |
| Cambio de 1 año* | -4.56% |
| Rango del día* | 25.72 - 27.24 |
| Rango de 52 semanas | 19.86-41.46 |
| Volumen medio (10 días) | 889.09K |
| Volumen medio (3 meses) | 12.82M |
| Capitalización de mercado | 3.57B |
| Ratio P/E | -100.00K |
| Acciones en circulación | 156.66M |
| Ingresos | N/A |
| EPS | -2.32 |
| Dividendo (Rendimiento %) | N/A |
| Beta | -100.00K |
| Próxima fecha de resultados | May 8, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 26.95 | 1.81 | 7.20% | 25.14 | 27.30 | 25.14 |
| Jun 28, 2022 | 26.94 | -0.93 | -3.34% | 27.87 | 29.13 | 26.80 |
| Jun 27, 2022 | 28.99 | 0.89 | 3.17% | 28.10 | 29.70 | 27.49 |
| Jun 24, 2022 | 28.08 | -0.17 | -0.60% | 28.25 | 29.09 | 27.63 |
| Jun 23, 2022 | 28.54 | 3.28 | 12.98% | 25.26 | 28.60 | 25.26 |
| Jun 22, 2022 | 26.05 | 1.34 | 5.42% | 24.71 | 26.24 | 24.71 |
| Jun 21, 2022 | 25.15 | -0.32 | -1.26% | 25.47 | 25.47 | 24.03 |
| Jun 17, 2022 | 23.86 | 0.20 | 0.85% | 23.66 | 24.42 | 23.16 |
| Jun 16, 2022 | 22.85 | -1.18 | -4.91% | 24.03 | 24.03 | 22.07 |
| Jun 15, 2022 | 24.53 | 0.31 | 1.28% | 24.22 | 24.87 | 23.33 |
| Jun 14, 2022 | 24.22 | 0.64 | 2.71% | 23.58 | 25.12 | 23.54 |
| Jun 13, 2022 | 23.87 | -0.71 | -2.89% | 24.58 | 24.67 | 23.20 |
| Jun 10, 2022 | 25.82 | -0.27 | -1.03% | 26.09 | 27.04 | 25.60 |
| Jun 9, 2022 | 27.99 | 0.51 | 1.86% | 27.48 | 28.92 | 27.48 |
| Jun 8, 2022 | 28.49 | 1.30 | 4.78% | 27.19 | 29.41 | 27.19 |
| Jun 7, 2022 | 28.72 | 3.24 | 12.72% | 25.48 | 28.84 | 25.48 |
| Jun 6, 2022 | 25.86 | -1.88 | -6.78% | 27.74 | 28.32 | 25.13 |
| Jun 3, 2022 | 27.78 | 1.02 | 3.81% | 26.76 | 28.51 | 26.76 |
| Jun 2, 2022 | 26.98 | 1.06 | 4.09% | 25.92 | 27.80 | 25.30 |
| Jun 1, 2022 | 26.37 | 0.40 | 1.54% | 25.97 | 26.76 | 25.02 |
Cerevel Therapeutics Holdings, Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| No events scheduled | ||
- Anual
- Trimestral
| 2021 | 2020 | 2019 | |
|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 |
| Ingresos de explotación | -220.098 | -149.116 | 0 |
| Ajuste por dilución | 0 | ||
| Beneficio neto diluido | -225.334 | -148.271 | 0 |
| Gastos totales de explotación | 220.098 | 149.116 | |
| Gastos de venta/general/administración Gastos, total | 58.243 | 45.813 | |
| Investigación y desarrollo | 161.855 | 103.303 | |
| Ingresos por intereses (gastos), netos No operativos | 0.157 | 0.224 | |
| Otros, netos | -5.393 | -3.274 | |
| Ingresos netos antes de impuestos | -225.334 | -152.166 | |
| Ingresos netos después de impuestos | -225.334 | -152.142 | |
| Beneficio neto antes de partidas extra. Elementos | -225.334 | -152.142 | |
| Ingresos netos | -225.334 | -152.142 | |
| Total Adjustments to Net Income | 0 | 3.871 | |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -225.334 | -148.271 | |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -225.334 | -148.271 | |
| Promedio ponderado de acciones diluidas | 136.577 | 73.6433 | |
| BPA diluido sin partidas extraordinarias | -1.64987 | -2.01337 | |
| BPA normalizado diluido | -1.64987 | -2.01337 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 | 0 | 0 |
| Gastos totales de explotación | 72.53 | 64.49 | 54.527 | 50.51 | 50.571 |
| Gastos de venta/general/administración Gastos, total | 17.507 | 16.649 | 14.368 | 13.216 | 14.01 |
| Investigación y desarrollo | 55.023 | 47.841 | 40.159 | 37.294 | 36.561 |
| Ingresos de explotación | -72.53 | -64.49 | -54.527 | -50.51 | -50.571 |
| Ingresos por intereses (gastos), netos No operativos | 0.295 | 0.119 | 0.013 | 0.01 | 0.015 |
| Otros, netos | 3.941 | 5.316 | -7.545 | -2.739 | -0.425 |
| Ingresos netos antes de impuestos | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
| Ingresos netos después de impuestos | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
| Beneficio neto antes de partidas extra. Elementos | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
| Ingresos netos | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
| Beneficio neto diluido | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
| Promedio ponderado de acciones diluidas | 147.985 | 147.392 | 144.022 | 127.482 | 127.226 |
| BPA diluido sin partidas extraordinarias | -0.46149 | -0.40067 | -0.4309 | -0.41762 | -0.40071 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -0.46149 | -0.40067 | -0.4309 | -0.41762 | -0.40071 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | |
|---|---|---|---|
| Total Activo Corriente | 578.017 | 390.56 | |
| Efectivo e inversiones a corto plazo | 565.688 | 383.623 | |
| Efectivo y Equivalentes | 193.018 | 383.623 | |
| Prepaid Expenses | 11.6 | 6.777 | |
| Other Current Assets, Total | 0.729 | 0.16 | |
| Total Assets | 688.919 | 445.273 | |
| Property/Plant/Equipment, Total - Net | 51.7 | 48.624 | |
| Property/Plant/Equipment, Total - Gross | 54.266 | 48.706 | |
| Accumulated Depreciation, Total | -2.566 | -0.082 | |
| Other Long Term Assets, Total | 6.933 | 6.089 | |
| Total Current Liabilities | 42.538 | 29.548 | |
| Accounts Payable | 11.298 | 4.993 | |
| Accrued Expenses | 30.865 | 24.282 | |
| Notes Payable/Short Term Debt | 0 | 0 | |
| Other Current Liabilities, Total | 0.375 | 0.273 | |
| Total Liabilities | 110.19 | 60.753 | |
| Total Long Term Debt | 33.54 | 0 | |
| Other Liabilities, Total | 34.112 | 31.205 | |
| Total Equity | 578.729 | 384.52 | |
| Common Stock | 0.015 | 0.013 | |
| Additional Paid-In Capital | 1195.94 | 775.417 | |
| Retained Earnings (Accumulated Deficit) | -616.244 | -390.91 | |
| Total Liabilities & Shareholders’ Equity | 688.919 | 445.273 | |
| Total Common Shares Outstanding | 147.72 | 127.124 | |
| Inversiones a corto plazo | 372.67 | ||
| Long Term Investments | 52.269 | ||
| Long Term Debt | 33.54 | ||
| Other Equity, Total | -0.986 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 553.55 | 578.017 | 675.029 | 331.782 | 349.811 |
| Efectivo e inversiones a corto plazo | 542.944 | 565.688 | 669.676 | 327.06 | 343.287 |
| Efectivo y Equivalentes | 91.764 | 193.018 | 669.676 | 327.06 | 343.287 |
| Prepaid Expenses | 10.004 | 11.6 | 5.257 | 4.597 | 6.362 |
| Other Current Assets, Total | 0.602 | 0.729 | 0.096 | 0.125 | 0.162 |
| Total Assets | 618.552 | 688.919 | 733.48 | 391.004 | 408.104 |
| Property/Plant/Equipment, Total - Net | 52.663 | 51.7 | 51.98 | 51.92 | 51.784 |
| Property/Plant/Equipment, Total - Gross | 56.299 | 54.266 | 53.526 | 52.552 | 51.876 |
| Accumulated Depreciation, Total | -3.636 | -2.566 | -1.546 | -0.632 | -0.092 |
| Other Long Term Assets, Total | 4.411 | 6.933 | 6.471 | 7.302 | 6.509 |
| Total Current Liabilities | 35.318 | 42.538 | 30.8 | 29.257 | 34.151 |
| Accounts Payable | 8.183 | 11.298 | 5.445 | 4.986 | 7.755 |
| Accrued Expenses | 26.442 | 30.865 | 24.928 | 23.939 | 26.241 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.693 | 0.375 | 0.427 | 0.332 | 0.155 |
| Total Liabilities | 97.053 | 110.19 | 104.4 | 97.117 | 68.068 |
| Total Long Term Debt | 28.324 | 33.54 | 38.612 | 32.242 | 0 |
| Other Liabilities, Total | 33.411 | 34.112 | 34.988 | 35.618 | 33.917 |
| Total Equity | 521.499 | 578.729 | 629.08 | 293.887 | 340.036 |
| Common Stock | 0.015 | 0.015 | 0.015 | 0.013 | 0.013 |
| Additional Paid-In Capital | 1207.36 | 1195.94 | 1186.79 | 789.004 | 781.914 |
| Retained Earnings (Accumulated Deficit) | -684.538 | -616.244 | -557.189 | -495.13 | -441.891 |
| Total Liabilities & Shareholders’ Equity | 618.552 | 688.919 | 733.48 | 391.004 | 408.104 |
| Total Common Shares Outstanding | 148.183 | 147.72 | 147.136 | 127.585 | 127.325 |
| Long Term Debt | 28.324 | 33.54 | 38.612 | 32.242 | |
| Other Equity, Total | -1.334 | -0.986 | -0.533 | ||
| Inversiones a corto plazo | 451.18 | 372.67 | |||
| Long Term Investments | 7.928 | 52.269 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | |
|---|---|---|---|
| Ingresos netos/Línea de salida | -225.334 | -152.142 | |
| Efectivo de actividades de explotación | -178.546 | -117.802 | |
| Efectivo de actividades de explotación | 2.731 | 0.397 | |
| Partidas no monetarias | 28.516 | 16.236 | |
| Cambios en el capital circulante | 15.541 | 17.707 | |
| Efectivo de actividades de inversión | -435.661 | -18.892 | |
| Gastos de capital | -10.503 | -18.892 | |
| Efectivo procedente de actividades de financiación | 423.602 | 440.835 | |
| Elementos de flujo de caja de financiación | -0.355 | 440.835 | |
| Variación neta de la tesorería | -190.605 | 304.141 | |
| Otras partidas de flujo de caja de inversión, total | -425.158 | ||
| Emisión (retiro) de acciones, neto | 392.707 | ||
| Emisión (amortización) de deuda, neta | 31.25 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -68.294 | -225.334 | -166.279 | -104.22 | -50.981 |
| Cash From Operating Activities | -67.648 | -178.546 | -125.802 | -82.026 | -36.418 |
| Cash From Operating Activities | 1.118 | 2.731 | 1.644 | 0.664 | 0.063 |
| Non-Cash Items | 4.935 | 28.516 | 27.551 | 14.084 | 6.377 |
| Changes in Working Capital | -5.407 | 15.541 | 11.282 | 7.446 | 8.123 |
| Cash From Investing Activities | -38.542 | -435.661 | -9.431 | -8.243 | -4.66 |
| Capital Expenditures | -2.197 | -10.503 | -9.431 | -8.243 | -4.66 |
| Cash From Financing Activities | 2.603 | 423.602 | 421.286 | 33.706 | 0.742 |
| Issuance (Retirement) of Stock, Net | 2.854 | 392.707 | 390.036 | 2.571 | 0.742 |
| Net Change in Cash | -103.587 | -190.605 | 286.053 | -56.563 | -40.336 |
| Financing Cash Flow Items | -0.251 | -0.355 | 0 | -0.115 | |
| Issuance (Retirement) of Debt, Net | 31.25 | 31.25 | 31.25 | ||
| Other Investing Cash Flow Items, Total | -36.345 | -425.158 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Bain Capital Private Equity, LP | Private Equity | 38.704 | 60632356 | 0 | 2022-12-31 | LOW |
| Pfizer Inc | Corporation | 17.4581 | 27349211 | 0 | 2022-08-16 | MED |
| Fidelity Management & Research Company LLC | Investment Advisor | 14.5879 | 22852917 | 67107 | 2022-12-31 | LOW |
| Perceptive Advisors LLC | Private Equity | 4.1567 | 6511727 | 0 | 2022-12-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.8476 | 6027510 | 164460 | 2022-12-31 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 3.027 | 4742044 | 1202 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.2049 | 3454078 | 288570 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.1858 | 3424220 | 704948 | 2022-12-31 | LOW |
| Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 1.8304 | 2867451 | -445882 | 2022-12-31 | LOW |
| Rock Springs Capital Management LP | Hedge Fund | 1.6 | 2506464 | 7316 | 2022-12-31 | LOW |
| T. Rowe Price Investment Management, Inc. | Investment Advisor | 1.2806 | 2006068 | 4631 | 2022-12-31 | MED |
| Invus Public Equities Advisors, LLC | Investment Advisor | 1.2128 | 1900000 | -100000 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7686 | 1204108 | 69847 | 2022-12-31 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 0.7349 | 1151321 | -231639 | 2022-12-31 | LOW |
| Lord, Abbett & Co. LLC | Investment Advisor | 0.7159 | 1121566 | 35610 | 2022-12-31 | MED |
| Hood River Capital Management LLC | Investment Advisor | 0.5896 | 923638 | 27066 | 2022-12-31 | MED |
| Alkeon Capital Management LLC | Investment Advisor/Hedge Fund | 0.5716 | 895509 | -87899 | 2022-12-31 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.4755 | 744853 | 7881 | 2022-12-31 | LOW |
| Novalis LifeSciences LLC | Private Equity | 0.4043 | 633350 | 0 | 2022-03-31 | |
| Fidelity Institutional Asset Management | Investment Advisor | 0.3602 | 564215 | 34460 | 2022-12-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Cerevel Therapeutics Holdings, Inc. Company profile
Sobre Cerevel Therapeutics Holdings Inc
Cerevel Therapeutics Holdings, Inc. es una empresa biofarmacéutica en fase clínica. La empresa combina la comprensión de la biología de las enfermedades y los neurocircuitos del cerebro con la química y la farmacología de los receptores del sistema nervioso central (SNC) para descubrir y diseñar nuevas terapias. La empresa se dedica al desarrollo de nuevas terapias para enfermedades neurocientíficas, como la esquizofrenia, la epilepsia y la enfermedad de Parkinson. Los productos candidatos de la empresa incluyen CVL-231, Darigabat, Tavapadon, CVL-871 y CVL-936. El candidato a producto de la Compañía, CVL-231, para el tratamiento de la esquizofrenia. Su Darigabat para el tratamiento de la epilepsia y la ansiedad. Su Tavapadon es un agonista parcial de la dopamina D1/D5 para el tratamiento de la enfermedad de Parkinson en fase temprana y tardía. Su producto candidato CVL-871 para el tratamiento de la apatía relacionada con la demencia. Su CVL-936 para el tratamiento del trastorno por consumo de sustancias (TCA).
| Industry: | Bio Therapeutic Drugs |
222 Jacobs Street
Suite 200
CAMBRIDGE
MASSACHUSETTS 02141
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com